

Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market Report and Forecast 2024-2032

Market Report | 2024-09-30 | 250 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$4999.00
- Five User License \$5999.00
- Corporate License \$6999.00

Report description:

Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market Report and Forecast 2024-2032

The Alpha-1 Antitrypsin Deficiency (AATD) treatment market was valued at USD 3 billion in 2023. It is expected to grow at a CAGR of 12.8% during the period 2024-2032 and attain a market value of USD 8.9 billion by 2032.

Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market Analysis

Alpha-1 Antitrypsin Deficiency (AATD) is a genetic condition characterised by insufficient levels of the protein alpha-1 antitrypsin (AAT) in the blood, which leads to an increased risk of lung and liver diseases. The AATD treatment market focuses on therapies designed to manage and alleviate symptoms associated with this deficiency. This market includes augmentation therapy, which involves intravenous infusion of AAT derived from human plasma, and other emerging treatments that aim to address the underlying genetic causes of the disorder.

Market Drivers

Increasing Awareness and Diagnosis: There is a growing awareness among healthcare providers and patients about AATD, leading to more diagnoses and, consequently, an increased demand for treatment options. Enhanced diagnostic tools and genetic screening are facilitating early detection, which is crucial for effective management.

Advancements in Treatment Options: The development of new and improved treatments is a significant driver in the AATD market. Innovations in gene therapy, protein replacement therapies, and the development of novel drugs are providing new avenues for managing the condition, thus expanding the market.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Rising Prevalence of Chronic Lung Diseases: AATD is often associated with chronic lung diseases such as emphysema and chronic obstructive pulmonary disease (COPD). As these conditions become more prevalent, the demand for AATD treatments increases, reflecting a broader market opportunity.

Supportive Government Policies: Government initiatives and support for rare disease research and treatment are fostering growth in the AATD treatment market. This includes funding for research and incentives for companies developing new therapies.

Challenges

High Treatment Costs: The cost of AAT replacement therapy is relatively high, which can limit access for patients, particularly in developing regions. The high cost of production and the need for specialised facilities contribute to these expenses.

Limited Awareness in Developing Markets: While awareness is increasing in developed countries, there is still a lack of awareness and diagnostic capabilities in many developing regions. This limits market growth potential in these areas.

Complexity of Treatment Administration: The current standard treatment, augmentation therapy, requires regular intravenous infusions, which can be burdensome for patients. This complexity can impact patient adherence and overall treatment efficacy.

Regulatory Challenges: Navigating the regulatory landscape for new treatments, especially gene therapies and novel drugs, can be complex and time-consuming. Rigorous regulatory requirements can delay the availability of new treatments in the market.

Future Opportunities

Emergence of Novel Therapies: Research into gene editing technologies and personalised medicine offers promising future opportunities for the AATD treatment market. Advances in these areas could lead to more effective and less invasive treatment options.

Expansion into Emerging Markets: As diagnostic capabilities and awareness improve globally, there is significant potential for market expansion into emerging economies. Increased investment in healthcare infrastructure in these regions could drive market growth.

Collaborations and Partnerships: Strategic collaborations between pharmaceutical companies, research institutions, and patient advocacy groups could accelerate the development of new therapies and enhance market reach. Partnerships may also help address the high cost of treatment through shared resources and expertise.

Technological Advancements: The integration of digital health technologies, such as telemedicine and remote monitoring, could improve patient management and adherence to treatment protocols, leading to better outcomes and market growth.

Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market Trends

The Alpha-1 Antitrypsin Deficiency (AATD) treatment market is undergoing significant evolution as advancements in medical research and technology pave the way for improved patient outcomes. Increasing awareness and innovative therapies are shaping the landscape, reflecting a dynamic shift in the management of this rare genetic disorder.

1. Growth of Augmentation Therapy

Augmentation therapy remains the cornerstone of AATD treatment, with increasing adoption driven by ongoing improvements in

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

product efficacy and safety. Recent advancements have focused on refining the process of producing and administering AAT, enhancing its effectiveness and reducing the risk of adverse reactions. The growing availability of high-quality AAT products is likely to continue driving market expansion.

2. Emergence of Gene Therapy

Gene therapy represents a transformative trend in the AATD market. Research into gene-editing technologies, such as CRISPR/Cas9, offers the potential to address the root cause of AATD by correcting genetic mutations. This approach could significantly alter treatment paradigms, providing long-term solutions and potentially reducing the need for regular infusions.

3. Increasing Focus on Early Diagnosis

Enhanced diagnostic capabilities and genetic screening programmes are playing a crucial role in identifying AATD at earlier stages. Early diagnosis not only improves patient outcomes but also drives market growth by increasing the demand for timely and effective treatment options. This trend underscores the importance of integrating AATD screening into routine healthcare practices.

4. Rising Investment in Research and Development

There is a notable increase in investment from both public and private sectors into research and development (R&D) for AATD treatments. Funding is being directed towards innovative therapies, including novel drugs and advanced delivery systems. This surge in R&D investment is expected to accelerate the development of new and improved treatment options.

5. Expansion into Emerging Markets

As awareness and diagnostic capabilities improve globally, emerging markets are becoming increasingly significant for AATD treatment. Pharmaceutical companies are expanding their reach into these regions, driven by a growing patient base and supportive government policies aimed at enhancing healthcare access.

6. Integration of Digital Health Technologies

The integration of digital health technologies, such as telemedicine and remote monitoring tools, is emerging as a trend in AATD management. These technologies facilitate better patient monitoring, adherence to treatment, and overall disease management, potentially improving outcomes and optimising treatment protocols.

These trends reflect a rapidly evolving market landscape, driven by technological advancements and a growing emphasis on personalised and effective treatment approaches for Alpha-1 Antitrypsin Deficiency.

Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market Segmentation

Market Breakup by Product Type

Bronchodilators

Oxygen Therapy

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Augmentation Therapy

Corticosteroids

The Alpha-1 Antitrypsin Deficiency (AATD) treatment market is significantly driven by advancements across various product types, including bronchodilators, oxygen therapy, augmentation therapy, and corticosteroids. Augmentation therapy, as a primary treatment, is seeing increased adoption due to its efficacy in replenishing deficient AAT levels, while bronchodilators and corticosteroids are essential for managing respiratory symptoms. Oxygen therapy remains crucial for patients with severe respiratory compromise. Future growth is anticipated as innovations enhance the effectiveness and accessibility of these therapies, driving market expansion. Collectively, these segments are poised to propel market growth throughout the forecast period by addressing diverse patient needs and improving treatment outcomes.

Market Breakup by Route of Administration

Oral

Parenteral

Inhalation

The Alpha-1 Antitrypsin Deficiency (AATD) treatment market is segmented by route of administration into oral, parenteral, and inhalation methods, each contributing uniquely to market growth. Parenteral administration, including intravenous infusions, remains a cornerstone for therapies like augmentation therapy, driving its widespread adoption due to its effectiveness. Inhalation therapies are gaining traction for their targeted delivery in respiratory management, offering convenience and improved patient compliance. Oral treatments, though less common, provide an alternative for certain therapeutic approaches. As advancements improve the efficacy and patient acceptance of these routes, the market is expected to expand, with each method enhancing overall treatment options and driving future growth.

Market Breakup by Region

United States

EU-4 and the United Kingdom

Germany

France

Italy

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Spain

United Kingdom

Japan

India

The Alpha-1 Antitrypsin Deficiency (AATD) treatment market shows significant regional variation, with key growth drivers in the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom. The US leads in market expansion due to high awareness and advanced treatment options. In Europe, Germany and France are notable for their robust healthcare systems and increasing patient access to therapies. Spain and Italy are also emerging markets with rising diagnostic capabilities. The UK continues to play a crucial role in market growth due to government support and healthcare infrastructure. Meanwhile, Japan and India present substantial growth opportunities driven by expanding healthcare access and increasing disease awareness.

Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market Competitive Landscape

The competitive landscape of the Alpha-1 Antitrypsin Deficiency (AATD) treatment market features prominent players such as Grifols, S.A., CSL Behring, Takeda Pharmaceutical Company Limited, Kamada Ltd, Arrowhead Pharmaceuticals, Inc., AstraZeneca PLC, and LFB Biomedicaments. These companies engage in various market activities, including strategic mergers and acquisitions to expand their portfolios and market presence. Research initiatives are a common focus, with significant investments in developing new therapies and enhancing existing treatments. Product introductions and innovations are frequently observed, reflecting ongoing efforts to improve efficacy and patient outcomes. Additionally, partnerships and collaborations are prevalent, aimed at leveraging complementary expertise and advancing research and development capabilities. This dynamic landscape highlights a competitive environment driven by continuous innovation and strategic growth activities.

Key Questions Answered in the Report

What is the current and future performance of the Alpha-1 Antitrypsin Deficiency (AATD) Treatment market?

What are the main challenges facing the Alpha-1 Antitrypsin Deficiency (AATD) Treatment market?

What are the key drivers of the Alpha-1 Antitrypsin Deficiency (AATD) Treatment market?

What emerging trends are shaping the future of the Alpha-1 Antitrypsin Deficiency (AATD) Treatment market?

How is augmentation therapy improving outcomes for patients with Alpha-1 Antitrypsin Deficiency?

Why is parenteral administration, including intravenous infusions, crucial for augmentation therapy in AATD?

Why does the US lead in market expansion for Alpha-1 Antitrypsin Deficiency treatments?

Key Benefits for Stakeholders

The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

trends, market forecasts, and dynamics of the Alpha-1 Antitrypsin Deficiency (AATD) treatment market from 2017-2032.

The research report provides the latest information on the market drivers, challenges, and opportunities in the Alpha-1 Antitrypsin Deficiency (AATD) treatment market.

The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.

Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the Alpha-1 Antitrypsin Deficiency (AATD) treatment industry and its attractiveness.

The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.

Table of Contents:

- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage - Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market Overview: 8 Major Market
 - 3.1 Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market Historical Value (2017-2023)
 - 3.2 Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market Forecast Value (2024-2032)
- 4 Vendor Positioning Analysis
 - 4.1 Key Vendors
 - 4.2 Prospective Leaders
 - 4.3 Niche Leaders
 - 4.4 Disruptors
- 5 Alpha-1 Antitrypsin Deficiency (AATD): Disease Overview
 - 5.1 Guidelines and Stages
 - 5.2 Pathophysiology
 - 5.3 Screening and Diagnosis
 - 5.4 Therapy Pathway
- 6 Patient Profile
 - 6.1 Patient Profile Overview
 - 6.2 Patient Psychology and Emotional Impact Factors
 - 6.3 Risk Assessment and Therapy Success Rate
- 7 Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market Epidemiology Scenario and Forecast - 8 Major Markets
 - 7.1 8MM Epidemiology Scenario Overview (2017-2032)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.1.1□Prevalence, by Country
 - 7.1.1.1□U.S.
 - 7.1.1.2□U.K.
 - 7.1.1.3□EU4
 - 7.1.1.4□India
 - 7.1.1.5□Japan
- 7.1.2□Mortality by Country
 - 7.1.2.1□U.S.
 - 7.1.2.2□U.K.
 - 7.1.2.3□EU4
 - 7.1.2.4□India
 - 7.1.2.5□Japan
- 7.1.3□Treatment Seeking Rate by Country
 - 7.1.3.1□U.S.
 - 7.1.3.2□U.K.
 - 7.1.3.3□EU4
 - 7.1.3.4□India
 - 7.1.3.5□Japan
- 8□Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market Landscape: 8 Major Market*
- 8.1□Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market: Developers Landscape
 - 8.1.1□Analysis by Year of Establishment
 - 8.1.2□Analysis by Company Size
 - 8.1.3□Analysis by Region
- 8.2□Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market: Product Landscape
 - 8.2.1□Analysis by Product Type
 - 8.2.2□Analysis by Route of Administration
- 9□Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market Therapy Challenges and Unmet Needs
 - 9.1□Therapy Pathway Challenges
 - 9.2□Compliance and Drop-Out Analysis
 - 9.3□Awareness and Prevention Gaps
- 10□Cost of Therapy□
- 11□Global Alpha-1 Antitrypsin Deficiency (AATD) Treatment: Market Dynamics
 - 11.1□Market Drivers and Constraints
 - 11.2□SWOT Analysis
 - 11.2.1□Strengths
 - 11.2.2□Weaknesses
 - 11.2.3□Opportunities
 - 11.2.4□Threats
 - 11.3□PESTEL Analysis
 - 11.3.1□Political
 - 11.3.2□Economic
 - 11.3.3□Social
 - 11.3.4□Technological
 - 11.3.5□Legal
 - 11.3.6□Environment
 - 11.4□Porter's Five Forces Model
 - 11.4.1□Bargaining Power of Suppliers

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11.4.2□Bargaining Power of Buyers
- 11.4.3□Threat of New Entrants
- 11.4.4□Threat of Substitutes
- 11.4.5□Degree of Rivalry
- 11.5□Key Demand Indicators
- 11.6□Key Price Indicators
- 11.7□Industry Events, Initiatives, and Trends
- 11.8□Value Chain Analysis
- 12□Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market Segmentation: 8 Major Market
- 12.1□Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market by Product Type
- 12.1.1□Market Overview
- 12.1.2□Bronchodilators
- 12.1.3□Oxygen Therapy
- 12.1.4□Augmentation Therapy
- 12.1.5□Corticosteroids
- 12.2□Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market by Route of Administration
- 12.2.1□Market Overview
- 12.2.2□Oral
- 12.2.3□Parenteral
- 12.2.4□Inhalation
- 12.3□Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market by Region
- 12.3.1□Market Overview
- 12.3.2□United States
- 12.3.3□EU-4 and the United Kingdom
- 12.3.3.1□Germany
- 12.3.3.2□France
- 12.3.3.3□Italy
- 12.3.3.4□Spain
- 12.3.3.5□United Kingdom
- 12.3.4□Japan
- 12.3.5□India
- 13□United States Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market (2017-2032)
- 13.1□United States Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market Historical Value (2017-2023)
- 13.2□United States Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market Forecast Value (2024-2032)
- 13.3□United States Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market by Product Type
- 13.3.1□Market Overview
- 13.3.2□Bronchodilators
- 13.3.3□Oxygen Therapy
- 13.3.4□Augmentation Therapy
- 13.3.5□Corticosteroids
- 13.4□United States Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market by Route of Administration
- 13.4.1□Market Overview
- 13.4.2□Oral
- 13.4.3□Parenteral
- 13.4.4□Inhalation
- 14□EU-4 and United Kingdom Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market (2017-2032)
- 14.1□EU-4 and United Kingdom Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market Historical Value (2017-2023)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 14.2 EU-4 and United Kingdom Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market Forecast Value (2024-2032)
- 14.3 EU-4 and United Kingdom Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market by Product Type
 - 14.3.1 Market Overview
 - 14.3.2 Bronchodilators
 - 14.3.3 Oxygen Therapy
 - 14.3.4 Augmentation Therapy
 - 14.3.5 Corticosteroids
- 14.4 EU-4 and United Kingdom Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market by Route of Administration
 - 14.4.1 Market Overview
 - 14.4.2 Oral
 - 14.4.3 Parenteral
 - 14.4.4 Inhalation
- 15 Japan Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
 - 15.1 Japan Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market Historical Value (2017-2023)
 - 15.2 Japan Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market Forecast Value (2024-2032)
 - 15.3 Japan Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market by Product Type
 - 15.3.1 Market Overview
 - 15.3.2 Bronchodilators
 - 15.3.3 Oxygen Therapy
 - 15.3.4 Augmentation Therapy
 - 15.3.5 Corticosteroids
 - 15.4 Japan Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market by Route of Administration
 - 15.4.1 Market Overview
 - 15.4.2 Oral
 - 15.4.3 Parenteral
 - 15.4.4 Inhalation
- 16 India Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
 - 16.1 India Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market (2017-2032) Historical Value (2017-2023)
 - 16.2 India Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market (2017-2032) Forecast Value (2024-2032)
 - 16.3 India Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market by Product Type
 - 16.3.1 Market Overview
 - 16.3.2 Bronchodilators
 - 16.3.3 Oxygen Therapy
 - 16.3.4 Augmentation Therapy
 - 16.3.5 Corticosteroids
 - 16.4 India Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market by Route of Administration
 - 16.4.1 Market Overview
 - 16.4.2 Oral
 - 16.4.3 Parenteral
 - 16.4.4 Inhalation
- 17 Regulatory Framework
 - 17.1 Regulatory Overview
 - 17.2 US FDA
 - 17.3 EU EMA
 - 17.4 INDIA CDSCO
 - 17.5 JAPAN PMDA
 - 17.6 Others

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 18□Patent Analysis
 - 18.1□ Analysis by Type of Patent
 - 18.2□ Analysis by Publication Year
 - 18.3□ Analysis by Issuing Authority
 - 18.4□ Analysis by Patent Age
 - 18.5□ Analysis by CPC Analysis
 - 18.6□ Analysis by Patent Valuation
 - 18.7□ Analysis by Key Players
- 19□Clinical Trial Analysis
 - 19.1□Analysis by Trial Registration Year
 - 19.2□Analysis by Trial Status
 - 19.3□Analysis by Trial Phase
 - 19.4□Analysis by Therapeutic Area
 - 19.5□Analysis by Geography
- 20□Grant Analysis
 - 20.1□Analysis by Year
 - 20.2□Analysis by Amount Awarded
 - 20.3□Analysis by Issuing Authority
 - 20.4□Analysis by Grant Product
 - 20.5□Analysis by Funding Institute
 - 20.6□Analysis by Departments
 - 20.7□Analysis by Recipient Organization
- 21□Funding and Investment Analysis
 - 21.1□ Analysis by Funding Instances
 - 21.2□ Analysis by Type of Funding
 - 21.3□ Analysis by Funding Amount
 - 21.4□ Analysis by Leading Players
 - 21.5□ Analysis by Leading Investors
 - 21.6□ Analysis by Geography
- 22□Strategic Initiatives
 - 22.1□ Analysis by Partnership Instances
 - 22.2□ Analysis by Type of Partnership
 - 22.3□ Analysis by Leading Players
 - 22.4□ Analysis by Geography
- 23□Supplier Landscape
 - 23.1□Market Share by Top 5 Companies
 - 23.2□Grifols, S.A .
 - 23.2.1□Financial Analysis
 - 23.2.2□Product Portfolio
 - 23.2.3□Demographic Reach and Achievements
 - 23.2.4□Mergers and Acquisitions
 - 23.2.5□Certifications
 - 23.3□CSL Behring
 - 23.3.1□Financial Analysis
 - 23.3.2□Product Portfolio
 - 23.3.3□Demographic Reach and Achievements
 - 23.3.4□Mergers and Acquisitions

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 23.3.5 Certifications
- 23.4 Takeda Pharmaceutical Company Limited
 - 23.4.1 Financial Analysis
 - 23.4.2 Product Portfolio
 - 23.4.3 Demographic Reach and Achievements
 - 23.4.4 Mergers and Acquisitions
 - 23.4.5 Certifications
- 23.5 Kamada Ltd
 - 23.5.1 Financial Analysis
 - 23.5.2 Product Portfolio
 - 23.5.3 Demographic Reach and Achievements
 - 23.5.4 Mergers and Acquisitions
 - 23.5.5 Certifications
- 23.6 Arrowhead Pharmaceuticals, Inc .
 - 23.6.1 Financial Analysis
 - 23.6.2 Product Portfolio
 - 23.6.3 Demographic Reach and Achievements
 - 23.6.4 Mergers and Acquisitions
 - 23.6.5 Certifications
- 23.7 AstraZeneca PLC
 - 23.7.1 Financial Analysis
 - 23.7.2 Product Portfolio
 - 23.7.3 Demographic Reach and Achievements
 - 23.7.4 Mergers and Acquisitions
 - 23.7.5 Certifications
- 23.8 LFB Biomedicaments
 - 23.8.1 Financial Analysis
 - 23.8.2 Product Portfolio
 - 23.8.3 Demographic Reach and Achievements
 - 23.8.4 Mergers and Acquisitions
 - 23.8.5 Certifications
 - 23.8.6

- 24 Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market - Distribution Model (Additional Insight)
 - 24.1 Overview
 - 24.2 Potential Distributors
 - 24.3 Key Parameters for Distribution Partner Assessment
- 25 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 26 Payment Methods (Additional Insight)
 - 26.1 Government Funded
 - 26.2 Private Insurance
 - 26.3 Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

**The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

**Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market Report and Forecast
2024-2032**

Market Report | 2024-09-30 | 250 pages | EMR Inc.

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4999.00
	Five User License	\$5999.00
	Corporate License	\$6999.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-06-26"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

